CN Patent

CN112912071A — 降低接受他汀类药物治疗的受试者对外周动脉血运重建的需求的方法

Assigned to Amarin Pharmaceuticals Ireland Ltd · Expires 2021-06-04 · 5y expired

What this patent protects

在多种实施方案中，本公开提供了诊断受试者对外周动脉血运重建的需求和/或通过向受试者施用包含约1g至约4g的二十碳五烯酸乙酯或其衍生物的药学上可接受的组合物来减少受试者对外周动脉血运重建的需求的方法。

USPTO Abstract

在多种实施方案中，本公开提供了诊断受试者对外周动脉血运重建的需求和/或通过向受试者施用包含约1g至约4g的二十碳五烯酸乙酯或其衍生物的药学上可接受的组合物来减少受试者对外周动脉血运重建的需求的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN112912071A
Jurisdiction
CN
Classification
—
Expires
2021-06-04
Drug substance claim
No
Drug product claim
No
Assignee
Amarin Pharmaceuticals Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.